Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.

NAFLD (non-alcoholic fatty liver disease) and AF (atrial fibrillation) are two pathological conditions that are highly prevalent in developed countries and share multiple risk factors. The relationship between NAFLD and AF in Type 2 diabetes is currently unknown. We studied a hospital-based sample of 702 patients with Type 2 diabetes discharged from our Division of Endocrinology during 2007-2011. The diagnosis of AF was confirmed in affected participants on the basis of ECGs and medical history by experienced cardiologists. NAFLD was defined by ultrasonographic detection of hepatic steatosis in the absence of other liver diseases. Of the 702 hospitalized patients included in the study, 514 (73.2%) of them had NAFLD and 85 (12.1%) had persistent or permanent AF. NAFLD was associated with an increased risk of prevalent AF {OR (odds ratio), 3.04 [95% CI (confidence interval), 1.54-6.02]; P<0.001}. Adjustments for age, sex, systolic BP (blood pressure), HbA1c, (glycated haemoglobin), estimated GFR (glomerular filtration rate), total cholesterol, electrocardiographic LVH (left ventricular hypertrophy), COPD (chronic obstructive pulmonary disease), and prior history of HF (heart failure), VHD (valvular heart disease) or hyperthyroidism did not attenuate the association between NAFLD and AF [adjusted OR, 5.88 (95% CI, 2.72-12.7); P<0.001]. In conclusion, our results show that ultrasound-diagnosed NAFLD is strongly associated with an increased prevalence of persistent or permanent AF in patients with Type 2 diabetes, independently of several clinical risk factors for AF. The potential impact of NAFLD on AF deserves particular attention, especially with respect to the implications for screening and surveillance strategies in the growing number of patients with NAFLD.

[1]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[2]  D. Levy,et al.  Influence of blood pressure on left atrial size. The Framingham Heart Study. , 1995, Hypertension.

[3]  L H Kuller,et al.  Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.

[4]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[5]  T. Gillebert,et al.  Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. , 1999, Cardiovascular research.

[6]  Cynthia A. Carnes,et al.  C-Reactive Protein Elevation in Patients With Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation , 2001, Circulation.

[7]  Bruce M Psaty,et al.  Inflammation as a Risk Factor for Atrial Fibrillation , 2003, Circulation.

[8]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[9]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[10]  S. Goland,et al.  Cardiac Abnormalities as a New Manifestation of Nonalcoholic Fatty Liver Disease: Echocardiographic and Tissue Doppler Imaging Assessment , 2006, Journal of clinical gastroenterology.

[11]  G. Targher,et al.  Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients , 2007, Diabetes Care.

[12]  S. Kimmel,et al.  Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population , 2008, Pharmacoepidemiology and drug safety.

[13]  R. Bhopal,et al.  Validity of electrocardiographic classification of left ventricular hypertrophy across adult ethnic groups with echocardiography as a standard. , 2008, Journal of electrocardiology.

[14]  Jeroen J. Bax,et al.  Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. , 2008, Journal of the American College of Cardiology.

[15]  M. Chonchol,et al.  Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. , 2009, Seminars in thrombosis and hemostasis.

[16]  Udo Hoffmann,et al.  Pericardial Fat, Intrathoracic Fat, and Measures of Left Ventricular Structure and Function: The Framingham Heart Study , 2009, Circulation.

[17]  M. Ermani,et al.  Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[18]  K. Reinier,et al.  Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation , 2009, Diabetes Care.

[19]  Udo Hoffmann,et al.  Pericardial Fat Is Associated With Prevalent Atrial Fibrillation: The Framingham Heart Study , 2010, Circulation. Arrhythmia and electrophysiology.

[20]  Chris Day,et al.  A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.

[21]  R. D'Agostino,et al.  Serum -Glutamyl Transferase and Risk of Heart Failure in the Community , 2010 .

[22]  X. Jouven,et al.  Mortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis , 2011, Circulation.

[23]  Eung Ju Kim,et al.  Total and Interatrial Epicardial Adipose Tissues Are Independently Associated With Left Atrial Remodeling in Patients With Atrial Fibrillation , 2011, Journal of cardiovascular electrophysiology.

[24]  D. Harnois,et al.  Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease , 2011 .

[25]  Q. Anstee,et al.  How big a problem is non-alcoholic fatty liver disease? , 2011, BMJ : British Medical Journal.

[26]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[27]  Eliseo Guallar,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[28]  Michael A Rosenberg,et al.  Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. , 2012, European heart journal.

[29]  Shih‐Ann Chen,et al.  Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation , 2012, Basic Research in Cardiology.

[30]  Enrico Barbieri,et al.  Nonalcoholic Fatty Liver Disease Is Associated With Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes , 2012, Diabetes Care.

[31]  G. Lip,et al.  Inflammation in atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[32]  P. Whincup,et al.  &ggr;-Glutamyltransferase, Hepatic Enzymes, and Risk of Incident Heart Failure in Older Men , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[33]  G. MacGowan,et al.  Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. , 2012, Journal of hepatology.

[34]  C. Byrne,et al.  Diagnosis and Management of Nonalcoholic Fatty Liver Disease and Its Hemostatic/Thrombotic and Vascular Complications , 2013, Seminars in Thrombosis & Hemostasis.

[35]  Christopher D Byrne,et al.  Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. , 2013, The Journal of clinical endocrinology and metabolism.

[36]  M. Rienstra,et al.  Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. , 2013, The American journal of cardiology.

[37]  Rahul Wadke,et al.  Atrial fibrillation. , 2022, Disease-a-month : DM.